Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02561871 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers
A Phase 1 study, sponsored by Crucell Holland.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02561871: Completed Phase 1 study, sponsored by Crucell Holland.
NCT02561871 is a Phase 1 study that has completed, run by Crucell Holland. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02561871, a Phase 1 study, has completed, sponsored by Crucell Holland.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of intramuscular prime-boost regimens of Ad26.RSV.FA2 given either once or twice followed by Ad35.RSV.FA2 (human adenovirus-vectored vaccine candidate) in healthy participants.
Interventions
- DRUG Placebo
- BIOLOGICAL Ad35.RSV.FA2
- BIOLOGICAL Ad26.RSV.FA2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02561871
The ClinicalTrials.gov registry entry for NCT02561871 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Crucell Holland, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02561871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02561871 about?
NCT02561871 is a clinical study titled "A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers". The purpose of this study is to assess the safety and tolerability of intramuscular prime-boost regimens of Ad26.RSV.FA2 given either once or twice followed by Ad35.RSV.FA2 (human adenovirus-vectored vaccine candidate) in healthy participants.
What is the current status of trial NCT02561871?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2015-09. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02561871?
The interventions under investigation include: Placebo (DRUG), Ad35.RSV.FA2 (BIOLOGICAL), Ad26.RSV.FA2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02561871?
This trial is sponsored by Crucell Holland, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.